← Russell 3000 cross-section

ANIP ANI PHARMACEUTICALS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$1.7bn
Revenue TTM
$978m
Net income TTM
$108m
Free cash flow
$173m
Composite score
77.9
Sector rank
#1720

Valuation

P / E
16.0
EV / EBITDA
EV / sales
1.7
FCF yield
9.96%
Earnings yield vs 10-yr
1.50pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
11.1%
EBITDA margin
ROE
18.1%
ROIC
29.1%
Revenue growth
30.9%

Insider activity, last 90 days

Net open-market
$-1.95m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The following table summarizes our results of operations for the periods indicated: The following table sets forth, for the periods indicated, items in our unaudited condensed consolidated statements of operations as a percentage of net revenues: 38 RESULTS OF OPERATIONS RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025 Net Revenue ____________________________________________ (1) There were no sales of YUTIQ during the quarters ended March 31, 2026 and June 30, 2026, as the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN, which has a combined label of DME and NIU-PS during the second quarter of 2025. …ANI PHARMACEUTICALS INC, 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →